Utang jangka dawa: leaptx.com (LPTX)

Leap Therapeutics, Inc. (LPTX) relies on a fabless business model, outsourcing compound synthesis and clinical trials to external contractors. This daily price chart on the GURU.Markets platform captured the 0.00 metric. The company develops targeted therapies for esophageal and gastric tumors using the DKN-01 antibody; however, research expenditures result in liquidity deficits and a continuous need for external financing.

Leap Therapeutics, Inc. (LPTX) oncology drug development is independent of macroeconomic cycles, making the company's capital structure a critical factor for its survival. Monitoring the organization's long-term financial debt allows for a real-time assessment of credit obligations with maturities exceeding one year, determining the balance between R&D investments and the risk of excessive debt leverage.